Amarin takes ap­pli­ca­tion to ex­pand Vas­cepa la­bel to the FDA as M&A chat­ter heats up

Hav­ing un­veiled an un­ex­pect­ed set of heart pro­tec­tive re­sults for their fish oil-de­rived pill Vas­cepa, Amarin is march­ing ahead to ful­fill block­buster ex­pec­ta­tions for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.